The mPFS of HR+/HER2- breast cancer cohort and TNBC cohort were 8.3 months (95% CI, 5.5–11.1 months) and 4.4 months (95% CI, 3.0 -7.3 months) respectively; with the median PFS of topo I-naive TNBC subgroup being 7.3 months (95% CI, 3.0–18.0 months).The mOS has not been reached for HR+/HER2- breast cancer cohort, while it was 13.5 months (95% CI, 10.1–16.3 months) for TNBC cohort; and 14.3 months for topo I-naive TNBC subgroup. This evidence concerns the gene ERBB2 and breast carcinoma.